SAT2 foot-and-mouth disease virus structurally modified for increased thermostability

Journal of Virology

Volumn 91, Issue 10, 2017, Pages

  Scott, Katherine A ^a,b   Kotecha, Abhay ^c   Seago, Julian ^d   Ren, Jingshan ^c   Fry, Elizabeth E ^c   Stuart, David I ^c,e   Charleston, Bryan ^d   Maree, Francois F ^a,b  

^a ONDERSTEPOORT VETERINARY INSTITUTE   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^e DIAMOND LIGHT SOURCE LTD   (United Kingdom)

Author keywords

FMDV; SAT2; Stability

Indexed keywords

COMPLEMENTARY DNA; FOOT AND MOUTH DISEASE VACCINE; MONOCLONAL ANTIBODY; PLASMID VECTOR; SODIUM CHLORIDE; ION; VACCINE; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; BHK CELL LINE; BIOASSAY; CONTROLLED STUDY; CYTOLYSIS; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; FOOT AND MOUTH DISEASE VIRUS SAT2; GENETIC STABILITY; GENETIC TRANSFECTION; GROWTH RATE; IONIC STRENGTH; NONHUMAN; PH; PRIORITY JOURNAL; RNA SYNTHESIS; SIMULATION; TEMPERATURE; THERMAL INACTIVATION ASSAY; THERMAL SHIFT ASSAY; THERMOSTABILITY; VACCINE PRODUCTION; VIRAL PHENOMENA AND FUNCTIONS; VIRAL PLAQUE ASSAY; VIROGENESIS; VIRUS MORPHOLOGY; VIRUS MUTANT; VIRUS PURIFICATION; VIRUS STABILITY; AMINO ACID SUBSTITUTION; ANIMAL; CHEMISTRY; GENETICS; GENOMIC INSTABILITY; IMMUNOLOGY; KINETICS; MUTATION; PHYSIOLOGY; SEROTYPE; VACCINE IMMUNOGENICITY;

AMINO ACID SUBSTITUTION; ANIMALS; FOOT-AND-MOUTH DISEASE VIRUS; GENOMIC INSTABILITY; HYDROGEN-ION CONCENTRATION; IMMUNOGENICITY, VACCINE; IONS; KINETICS; MUTATION; SEROGROUP; SODIUM CHLORIDE; TEMPERATURE; VACCINE POTENCY; VIRAL VACCINES;

EID: 85018244544     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02312-16     Document Type: Article

References (64)

1. Mateu MG, da Silva JL, Rocha E, de Brum DL, Alonso A, Enjuanes L, Domingo E, Barahona H. 1988. Extensive antigenic heterogeneity of foot-and-mouth disease virus of serotype C. Virology 167:113-124. https://doi.org/10.1016/0042-6822(88)90060-8.
2. Martínez MA, Dopazo J, Hernández J, Mateu MG, Sobrino F, Domingo E, Knowles NJ. 1992. Evolution of the capsid protein genes of foot-andmouth disease virus. Antigenic variation without accumulation of amino acid substitutions over six decades. J Virol 66:3557-3565.
3. Domingo E, Diez J, Martinez MA, Hernandez JH, Holguin A, Borrego B, Mateu MG. 1993. New observations on antigenic diversification of RNA viruses. Antigenic variation is not dependent on immune selection. J Gen Virol 74:2039-2045.
4. Knight-Jones TJ, Rushton J. 2013. The economic impacts of foot and mouth disease-what are they, how big are they and where do they occur? Prev Vet Med 112:161-173. https://doi.org/10.1016/j.prevetmed .2013.07.013.
5. Scoones I, Bishi A, Mapitse N, Moerane R, Penrith ML, Sibanda R, Thomson G, Wolmer W. 2010. Foot-and-mouth disease and market access: challenges for the beef industry in southern Africa. Development 1:135-164.
6. Perry BD, Randolph TF. 2003. The economics of foot-and-mouth disease, its control and its eradication, p 23-41. In Dodet B, Vicari M (ed), Foot-and-mouth disease: control strategies. éditions scientifiques et médicales. Elsevier SAS, France.
7. Rweyemamu M, Roeder P, Mackay D, Sumption K, Brownlie J, Leforban Y, Valarcher JF, Knowles NJ, Saraiva V. 2008. Epidemiological patterns of foot-and-mouth disease worldwide. Transbound Emerg Dis 55:57-72. https://doi.org/10.1111/j.1865-1682.2007.01013.x.
8. Hedger RS. 1972. Foot-and-mouth disease and the African buffalo (Syncerus caffer). J Comp Pathol 82:19-28. https://doi.org/10.1016/0021-9975(72)90022-9.
9. Hedger RS, Condy JB, Golding SM. 1972. Infection of some species of African wildlife with foot-and-mouth disease virus. J Comp Pathol 82: 455-461. https://doi.org/10.1016/0021-9975(72)90045-X.
10. Bengis RG, Kock RA, Fischer J. 2002. Infectious animal diseases: the wildlife/livestock interface. Rev Sci Tech 21:53-65.
11. Thomson GR, Vosloo W, Bastos AD. 2003. Foot and mouth disease in wildlife. Virus Res 91:145-161. https://doi.org/10.1016/S0168-1702(02)00263-0.
12. Vosloo W, Bastos AD, Kirkbride E, Bengis RG, Keet DF, Thomson G. 1996. Persistent infection of African buffalo (Syncerus caffer) with SAT-type foot-and-mouth disease viruses: rate of fixation of mutations, antigenic change and interspecies transmission. J Gen Virol 77:1457-1467. https:// doi.org/10.1099/0022-1317-77-7-1457.
13. Vosloo W, Bastos AD, Sangare O, Hargreaves SK, Thomson GR. 2002. Review of the status and control of foot-and-mouth disease in sub-Saharan Africa. Rev Sci Tech 21:437-449.
14. Ayebazibwe C, Mwiine FN, Tjornehoj K, Balinda SN, Muwanika VB, Ademun Okurut AR, Belsham GJ, Norman P, Siegismund HR, Alexandersen S. 2010. The role of African buffalos (Syncerus caffer) in the maintenance of foot-and-mouth disease in Uganda. BMC Vet Res 6:54. https://doi.org/ 10.1186/1746-6148-6-54.
15. Dawe PS, Flanagan FO, Madekurozwa RL, Sorensen KJ, Anderson EC, Foggin CM, Ferris NP, Knowles NJ. 1994. Natural transmission of footand-mouth disease virus from African buffalo (Syncerus caffer) to cattle in a wildlife area of Zimbabwe. Vet Rec 134:230-232. https://doi.org/10 .1136/vr.134.10.230.
16. Thomson GR. 1994. Foot-and-mouth disease, p 825-852. In Coetzer JAW, Thomson GR, Tustin RC (ed), Foot-and-mouth disease. Oxford University Press, Cape Town, South Africa.
17. Bastos AD, Boshoff CI, Keet DF, Bengis RG, Thomson GR. 2000. Natural transmission of foot-and-mouth disease virus between African buffalo (Syncerus caffer) and impala (Aepyceros melampus) in the Kruger National Park, South Africa. Epidemiol Infect 124:591-598. https://doi.org/10 .1017/S0950268899004008.
18. Vosloo W, Thomson GR. 2004. Natural habitats in which foot-and-mouth disease viruses are maintained, p 384-410. In Domingo E, Sobrino F (ed), Foot-and-mouth disease: current perspectives. Horizon Bioscience, Norfolk, United Kingdom.
19. Jori F, Caron A, Thompson PN, Dwarka R, Foggin C, de Garine-Wichatitsky M, Hofmeyr M, van Heerden J, Heath L. 2014. Characteristics of foot-and-mouth disease viral strains circulating at the wildlife/ livestock interface of the Great Limpopo Transfrontier conservation area. Transbound Emerg Dis 63:e58-e70. https://doi.org/10.1111/tbed.12231.
20. Ahmed HA, Salem SA, Habashi AR, Arafa AA, Aggour MGA, Salem GH, Gaber AS, Selem O, Abdelkader SH, Knowles NJ, Madi M, Valdazo-González B, Wadsworth J, Hutchings GH, Mioulet V, Hammond JM, King DP. 2012. Emergence of foot-and-mouth disease virus SAT2 in Egypt during 2012. Transbound Emerg Dis 59:476-481. https://doi.org/10 .1111/tbed.12015.
21. Chardonnet P, des Clers B, Fischer J, Gerhold R, Jori F, Lamarque F. 2002. The value of wildlife. Rev Sci Tech 21:15-51.
22. Brückner GK, Vosloo W, Du Plessis BJ, Kloeck PE, Connoway L, Ekron MD, Weaver DB, Dickason CJ, Schreuder FJ, Marais T, Mogajane ME. 2002. Foot-and-mouth disease: the experience of South Africa. Rev Sci Tech 21:751-776.
23. Doel TR, Baccarini PJ. 1981. Thermal stability of foot-and-mouth disease virus. Arch Virol 70:21-32. https://doi.org/10.1007/BF01320790.
24. Rossmann MG, Johnson JE. 1989. Icosahedral RNA virus structure. Annu Rev Biochem 58:533-573.
25. Fry E, Logan D, Acharya R, Fox G, Rowlands D, Brow R, Stuart D. 1990. Architecture and topography of an aphthovirus. Semin Virol 1:439-451.
26. Reguera J, Carreura A, Roilobos L, Almendral JM, Mateu MG. 2004. Role of interfacial amino acid residues in assembly, stability, and conformation of a spherical virus capsid. Proc Natl Acad Sci U S A 101:2724-2729. https://doi.org/10.1073/pnas.0307748101.
27. Reguera J, Grueso E, Carreira A, Sánchez-Martínez C, Almendral JM. 2005. Functional relevance of amino acid residues involved in interactions with ordered nucleic acid in a spherical virus. J Biol Chem 280: 17969-17977. https://doi.org/10.1074/jbc.M500867200.
28. Mateo R, Diaz A, Baranowski E, Mateu MG. 2003. Complete alanine scanning of intersubunit interfaces in a foot-and-mouth disease virus capsid reveals critical contributions of many side chains to particle stability and viral function. J Biol Chem 278:41019-41027. https://doi .org/10.1074/jbc.M304990200.
29. Acharya R, Fry E, Stuart D, Fox G, Rowlands D, Brown F. 1989. The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Nature 337:709-716. https://doi.org/10.1038/337709a0.
30. Curry S, Fry E, Blakemore W, Abu-Ghazaleh R, Jackson T. 1996. Perturbations in the surface structure of A22 Iraq foot-and-mouth disease virus accompanying coupled changes in host cell specificity and antigenicity. Structure 4:135-145. https://doi.org/10.1016/S0969-2126(96)00017-2.
31. Ellard FM, Drew J, Blakemore WE, Stuart DI, King AM. 1999. Evidence for the role of His-142 of protein 1C in the acid-induced disassembly of foot-and-mouth disease virus capsids. J Gen Virol 80:1911-1918. https:// doi.org/10.1099/0022-1317-80-8-1911.
32. Mateo R, Luna E, Rincon V, Mateu MG. 2008. Engineering viable footand-mouth disease viruses with increased thermostability as a step in the development of improved vaccines. J Virol 82:12232-12240. https:// doi.org/10.1128/JVI.01553-08.
33. Maree FF, Kasanga CJ, Scott KA, Opperman PA, Chitray M, Sangula A, Sallu R, Sinkala Y, Wambura P, King DP, Paton D, Rweyamamu MM. 2014. Challenges and prospects for the control of foot-and-mouth disease: an African perspective. J Vet Med Res Rep 5:119-138.
34. Doel TR, Chong WKT. 1982. Comparative immunogenicity of 146S, 75S and 12S particles of foot-and-mouth disease virus. Arch Virol 73: 185-191. https://doi.org/10.1007/BF01314726.
35. Kotecha A, Seago J, Scott K, Burman A, Loureiro S, Ren J, Porta C, Ginn HM, Jackson T, Perez-Martin E, Siebert CA, Paul G, Huiskonen JT, Jones IM, Esnouf RM, Fry EE, Maree FF, Charleston B, Stuart DI. 2015. Structurebased energetics of protein interfaces guides foot-and-mouth disease virus vaccine design. Nat Struct Mol Biol 22:788-794. https://doi.org/10 .1038/nsmb.3096.
36. Reeve R, Blignaut B, Esterhuysen JJ, Opperman P, Matthews L, Fry EE, de Beer TAP, Theron J, Rieder E, Vosloo W, O'Neill HG, Haydon DT, Maree FF. 2010. Sequence-based prediction for vaccine strain selection and identification of antigenic variability in foot-and-mouth disease virus. PLoS Comput Biol 6:e1001027. https://doi.org/10.1371/journal.pcbi.1001027.
37. Curry S, Abrams CC, Fry E, Crowther JC, Belsham GJ, Stuart DI, King AMQ. 1995. Viral RNA modulates the acid sensitivity of foot-and-mouth disease virus capsids. J Virol 69:430-438.
38. Van Rensburg HG, Henry T, Mason PW. 2004. Studies of genetically defined chimeras of a European type A virus and a South African Territories type 2 virus reveal growth determinants for foot-and-mouth disease virus. J Gen Virol 85:61-68. https://doi.org/10.1099/vir.0.19509-0.
39. Brehm KE, Ferris NP, Lenk M, Riebe R, Haas B. 2009. Highly sensitive fetal goat tongue cell line for detection and isolation of foot-and-mouth disease virus. J Clin Microbiol 47:3156-3160. https://doi.org/10.1128/ JCM.00510-09.
40. Opperman PA, Rotherham LS, Esterhuyzen J, Charleston B, Juleff N, Capozzo AV, Theron J, Maree FF. 2014. Determining the epitope dominance on the capsid of a serotype SAT2 foot-and-mouth disease virus by mutational analyses. J Virol 88:8307-8318. https://doi.org/10.1128/JVI .00470-14.
41. Walter TS, Renm J, Tuthill TJ, Rowlands DJ, Stuart DI, Fry EE. 2012. A plate-based high throughput assay for virus stability and vaccine formulation. J Virol Methods 185:166-170. https://doi.org/10.1016/j .jviromet.2012.06.014.
42. Porta C, Kotecha A, Burman A, Jackson T, Ren J, Loureiro S, Jones IM, Fry EE, Stuart DI, Charleston B. 2013. Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. PLoS Pathog 9:e1003255. https://doi.org/10.1371/journal.ppat.1003255.
43. Mateo R, Luna E, Mateu MG. 2007. Thermostable variants are not generally represented in foot-and-mouth disease virus quasispecies. J Gen Virol 88:859-864. https://doi.org/10.1099/vir.0.82521-0.
44. Hegde NR, Maddur MS, Rao PP, Kaveri SV, Bayry J. 2009. Thermostable foot-and-mouth disease virus as a vaccine candidate for endemic countries: a perspective. Vaccine 27:2199-2201. https://doi.org/10.1016/ j.vaccine.2009.01.032.
45. O'Donnell V, La Rocco M, Duque H, Baxt B. 2005. Analysis of foot-andmouth disease virus internalization events in cultured cells. J Virol 79:8506-8518. https://doi.org/10.1128/JVI.79.13.8506-8518.2005.
46. Rincón V, Rodriguez-Huete A, Lopez-Arguello S, Ibarra-Molero B, Sanchez-Ruiz JM, Harmsen MM, Mateu MG. 2014. Identification of the structural basis of thermal lability of a virus provides a rationale for improved vaccines. Structure 22:1560-1570. https://doi.org/10.1016/j.str .2014.08.019.
47. Zhou JH, Zhang J, Chen HT, Ma LN, Ding YZ, Peisak Z, Liu YS. 2011. The codon usage model of the context flanking each cleavage site in the polyprotein of foot-and-mouth disease virus. Infect Genet Evol 11: 1815-1819. https://doi.org/10.1016/j.meegid.2011.07.014.
48. Macadam AJ, Ferguson G, Stone DM, Meredith J, Knowlson S, Auda G, Almond JW, Minor PD. 2006. Rational design of genetically stable liveattenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol 80:8653-8663. https://doi.org/10.1128/JVI .00370-06.
49. Luongo C, Winter CC, Collins PL, Buchholz UJ. 2012. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol 86: 10792-10804. https://doi.org/10.1128/JVI.01227-12.
50. Colman PM, Varghese JN, Laver WG. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41-44. https://doi.org/10.1038/303041a0.
51. Colman PM. 1997. Virus versus antibody. Structure 5:591-593. https:// doi.org/10.1016/S0969-2126(97)00214-1.
52. Lin G, Nara PL. 2007. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr HIV Res 5:514-541. https://doi.org/10.2174/157016207782418489.
53. Kotecha A, Zhang F, Juleff N, Jackson T, Perez E, Stuart D, Fry E, Charleston B, Seago J. 2016. Application of the Thermofluor PaSTRy technique for improving foot-and-mouth disease virus vaccine formulation. J Gen Virol 97:1557-1565. https://doi.org/10.1099/jgv.0.000462.
54. van Vlijmen HWT, Curry S, Schaefer M, Karplus M. 1998. Titration calculations of foot-and-mouth disease virus capsid and their stabilities as a function of pH. J Mol Biol 275:295-308. https://doi.org/10.1006/jmbi .1997.1418.
55. Wang X, Peng W, Ren J, Hu Z, Jiwei X, Lou Z, Li X, Yin W, Shen X, Porta C. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19:424-429. https://doi.org/10 .1038/nsmb.2255.
56. Basavappa R, Syed R, Flore O, Icenogle JP, Filman DJ, Hogle JM. 1994. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution. Protein Sci 3:1651-1669. https://doi.org/10.1002/pro.5560031005.
57. Rieder E, Bunch T, Brown F, Mason PW. 1993. Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol 67:5139-5145.
58. Case DA, Cheatham TE, Darden T, Gohlke DT, Luo R, Merz KM. 2005. The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688. https://doi.org/10.1002/jcc.20290.
59. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W. 2000. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889-897. https://doi.org/10.1021/ar000033j.
60. Bastos AD, Haydon DT, Forsberg R, Knowles NJ, Anderson EC, Bengis RG, Nel LH, Thomson GR. 2001. Genetic heterogeneity of SAT-1 type footand-mouth disease viruses in southern Africa. Arch Virol 146:1537-1551. https://doi.org/10.1007/s007050170077.
61. Knipe T, Rieder E, Baxt B, Ward G, Mason PW. 1997. Characterization of synthetic foot-and-mouth disease virus provirions separates acidmediated disassembly from infectivity. J Virol 71:2851-2856.
62. Mateo R, Mateu MG. 2007. Deterministic, compensatory mutational events in the capsid of foot-and-mouth disease virus in response to the introduction of mutations found in viruses from persistent infections. J Virol 81:1879-1887. https://doi.org/10.1128/JVI.01899-06.
63. Doel TR, Mowat GN. 1985. An international collaborative study on foot and mouth disease virus assay methods. 2. Quantification of 146S particles. J Biol Stand 13:335-344. https://doi.org/10.1016/S0092-1157 (85)80048-2.
64. Moraes MP, Mayr GA, Mason PW, Grubman MJ. 2002. Early protection against homologous challenge after a single dose of replicationdefective human adenovirus type 5 expressing capsid proteins of footand-mouth disease virus (FMDV) strain A24. Vaccine 20:1631-1639. https://doi.org/10.1016/S0264-410X(01)00483-2.